December 27, 2022
NOT-CA-23-050 - Notice of Request for Proposals (RFP), Solicitation 75N91023R00034: NATIONAL CANCER INSTITUTE (NCI) SMALL BUSINESS INNOVATION RESEARCH (SBIR) INNOVATIVE CONCEPT AWARD PROGRAM
NOT-CA-23-034 Notice of Request for Proposals (RFP), Solicitation 75N91023R00024: PREVENT Cancer Preclinical Drug Development Program
National Cancer Institute (NCI)
Presolicitation Announcement
Solicitation 75N91023R00024 can be found at the www.sam.gov site.
Description:
NCI will post a solicitation for the PREVENT Cancer Preclinical Drug Development Program to procure research & development services in support the NCI PREVENT Cancer Preclinical Drug Development Program (PREVENT; http://prevention.cancer.gov/major-programs/prevent-cancer-preclinical) with its primary mission to advance the preclinical development of cancer-preventive interventions and intermediate biomarkers.
The PREVENT program requires services under three (3) separate multiple-award IDIQ pools: 1) Preclinical Efficacy and Intermediate Endpoint Biomarkers (Efficacy), 2) Preclinical Services for Biopharmaceutical Product Development and Manufacturing (Current Good Manufacturing Practices or cGMP), and 3) Toxicology and Pharmacology Testing (Toxicology). No proposal responses are requested at this time, and a formal acquisition solicitation/Request for Proposals (RFP) will be issued in Winter 2022/2023.
Potential interested parties are expected to review this notice of proposed contract action available at https://sam.gov/opp/2e5b6d7ba278444e943be5cd94ecfee8/view for additional details and to review the Statements of Work attached to the notice.
The Statements of Work for each pool include the following tasks:
- Efficacy Pool: (1) preclinical evaluation of cancer preventive efficacy; (2) evaluation and validation of intermediate endpoints for chemopreventive agents; and (3) evaluation and validation of intermediate endpoints for immunopreventive agents
- CGMP Pool: (1) product development planning and evaluation; (2) analytical assay development and product characterization; (3) process development and related activities; and (4) CGMP manufacture related activities and documentation
- Toxicology Pool: (1) genotoxicity testing; (2) general toxicity in experimental animals; (3) reproductive toxicology studies in rodents and rabbits; and (4) specialized studies.
The RFP is anticipated to result in approximately 25 awards, with up to ten (10) in the Efficacy pool, up to five in the CGMP pool, and up to ten (10) in the Toxicology pool. Awards are anticipated in November 2023 to Offerors capable of performing the work described in the Statements of Work available through www.sam.gov (internet address above). Task orders issued under the IDIQ contract(s) are anticipated to be either cost-plus-fixed-fee (CPFF), cost-reimbursement (CR) or firm fixed price (FFP). The duration of the IDIQ contract(s) is anticipated to be for a five (5) year period with two (2) one (1)-year option periods (for a total length of seven (7) years if all option periods are exercised).
This advertisement does not commit the United States Federal Government to award any contract. The NAICS code for this acquisition is 541714, with a size standard of 1,000 employees.
Place of Performance:
- The place of performance will be the Contractor’s work site.
Set-Aside Status:
- None.
Proposed release of RFP:
The RFP Solicitation 75N91023R00024 is scheduled for electronic release on or about January 4, 2023.
The RFP will only be available electronically and must be accessed through the Office of Acquisitions, NCI homepage by using the following address: http://rcb.cancer.gov/rcb-internet/ or through sam.gov https://www.sam.gov/. All information required for submission of a proposal will be contained in the electronic Request for Proposal (RFP) package. No collect calls or facsimile transmissions will be accepted. It is the offerors' responsibility to monitor the above-mentioned sites for release of the solicitation and any amendments. All responsible sources may submit a proposal, which shall be considered by the agency.
POTENTIAL OFFERORS WILL BE RESPONSIBLE FOR DOWNLOADING THEIR OWN COPY OF THE SOLICITATION AND ANY AMENDMENTS THAT MAY BE ISSUED. FAILURE TO DO SO WILL BE AT THE OFFEROR’s OWN RISK. ALL INQUIRIES SHALL BE SUBMITTED ELECTRONICALLY TO THE CONTRACTING OFFICER(S) LISTED AS THE POINT OF CONTACT BELOW.
Contracting Office Address: Department of Health and Human Services, National Institutes of Health (NIH), National Cancer Institute (NCI), Office of Acquisitions (OA), Riverside Five, 8490 Progress Drive, Suite 400, Frederick, MD 21701
Rich Taylor
NIH/NCI/OA/TSB
Telephone: 717-339-9735
Email: [email protected]
and Human Services (HHS)
